These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 7625371

  • 21. Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer.
    van Zandwijk N, ten Bokkel Huinink WW, Wanders J, Simonetti G, Dubbelman R, Franklin H, van Tinteren H, McVie JG.
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):16-9. PubMed ID: 2154854
    [Abstract] [Full Text] [Related]

  • 22. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL, Zhang XR, Liu JW, Chen ZY, Lin YC, Wang YD, Chen Q, Nan KJ, Song SP, Han FC, Zhu YZ, Li LY, Zheng YH, Chu DT.
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [Abstract] [Full Text] [Related]

  • 23. Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer.
    Manegold C, Bischoff H, Fischer JR, Löchner S, Peukert M, Schmähl A, Drings P.
    Ann Oncol; 1992 Nov; 3(9):723-6. PubMed ID: 1333266
    [Abstract] [Full Text] [Related]

  • 24. Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
    Shepherd FA, Evans WK, Goss PE, Latreille J, Logan D, Maroun J, Stewart D, Warner E, Paul K.
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):54-8. PubMed ID: 1329213
    [Abstract] [Full Text] [Related]

  • 25. Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer.
    Hsieh RK, Chang AY, Boros L, Asbury R.
    Am J Clin Oncol; 1994 Dec; 17(6):509-13. PubMed ID: 7977171
    [Abstract] [Full Text] [Related]

  • 26. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Specenier P, Rasschaert M, Van den Brande J, Dyck J, Schrijvers D, Huizing MT, Vermorken JB.
    Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
    Hoffman PC, Masters GA, Drinkard LC, Krauss SA, Samuels BL, Golomb HM, Vokes EE.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):11-5. PubMed ID: 8677441
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Phase I study of high-dose cisplatin, ifosfamide, and etoposide.
    Perez EA, Sowray PC, Gardner SL, Gandara DR.
    Cancer Chemother Pharmacol; 1994 Jun; 34(4):331-4. PubMed ID: 8033300
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
    Budd GT, Metch B, Weiss SA, Weick JK, Fabian C, Stephens RL, Balcerzak SP.
    Cancer Chemother Pharmacol; 1993 Jun; 31 Suppl 2():S213-6. PubMed ID: 8453701
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.